News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gyros AB Announces Changes to its Management Team


10/20/2011 12:21:07 PM

20 October 2011, Uppsala, Sweden: Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, today announced the appointment of Dr. Jon-Sverre Schanche as Chief Technology Officer and Vice President Technical Affairs. Dr. Schanche’s appointment comes as Nils Kristensen, COO and VP Technical Operations, and Stephan Hoffmann, VP Business Development, leave the company.

Dr. Schanche has almost thirty years of industrial R&D and management experience. In his new role he will hold responsibility for business and product development as well as production and manufacturing. Most recently, Dr. Schanche was Vice President R&D at DAKO Denmark A/S where he established a system development organization for in vitro diagnostic products. Before this, he held executive roles within the drug discovery and biotechnology supply industry, including Vice President of R&D in Personal Chemistry AB and Biotage AB and several senior management positions in Amersham Pharmacia Biotech (now GE Healthcare), including General Manager for the Norwegian R&D site.

Erik Walldén, CEO at Gyros, commented, “We are extremely pleased to make this appointment. Dr. Schanche brings a wealth of experience that will further enhance Gyros’ ability to develop its nanoscale immunoassay platform for time-critical workflows in the biopharmaceutical industry”.

For a high resolution image of Dr. Schanche please contact Zyme Communications

About Gyros AB www.gyros.com

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.

Enquiries:

Katie Odgaard

Zyme Communications Ltd

Tel: +44 (0) 7787 502 947

Skype: kodgaard

Email: katie.odgaard@zymecommunications.com

www.zymecommunications.com


Read at BioSpace.com


comments powered by Disqus
Gyros AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES